Physician profile
Troy Bertoli
NPI 1518189448
$947.34
in general payments reported to CMS, 2019-2025
11 companies · $259 in 2025
The $259 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $242 · 2022: $162 · 2023: $33.80 · 2024: $251 · 2025: $259.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $544.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $543.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $182.59 | 2019-2024 | Jardiance |
| Lilly USA, LLC | $151.64 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $140.17 | 2019-2025 | Wegovy |
| Medtronic, INC. | $101.29 | 2024 | Venaseal |
| Edwards Lifesciences Corporation | $96.15 | 2025 | Pascal |
| Amarin Pharma, INC. | $67.87 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $52.77 | 2019 | |
| Amgen INC. | $52.69 | 2019-2025 | Repatha, Otezla |
| Biohaven Pharmaceutical Holding Company Ltd. | $42.29 | 2022 | |
| Glaxosmithkline, LLC. | $34.80 | 2022-2023 | Arexvy |
| Gilead Sciences, INC. | $25.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Troy Bertoli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.